Search by Drug Name or NDC
NDC 59922-0631-01 Auryxia 210 mg/1 Details
Auryxia 210 mg/1
Auryxia is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Akebia Therapeutics, Inc.. The primary component is TETRAFERRIC TRICITRATE DECAHYDRATE.
MedlinePlus Drug Summary
Ferric citrate is used to control high blood levels of phosphorus in people with chronic kidney disease who are on dialysis (medical treatment to clean the blood when the kidneys are not working properly). Ferric citrate is also used to treat iron-deficiency anemia (a lower than normal number of red blood cells due to too little iron) in adults with chronic kidney disease (damage to the kidneys which may worsen over time and may cause the kidneys to stop working) who are not on dialysis. Ferric citrate is in a class of medications called phosphate binders and iron replacement products. It works to control high blood levels of phosphorus by binding phosphorus that you get from foods in your diet and prevents it from being absorbed into your blood stream. It works to treat iron-deficiency anemia by replenishing iron stores so that the body can make more red blood cells.
Related Packages: 59922-0631-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Ferric Citrate
Product Information
NDC | 59922-0631 |
---|---|
Product ID | 59922-631_5d48b527-3cbb-44e3-aadf-94f2d0bf1445 |
Associated GPIs | 52800030100320 |
GCN Sequence Number | 072787 |
GCN Sequence Number Description | ferric citrate TABLET 210MG IRON ORAL |
HIC3 | C1A |
HIC3 Description | ELECTROLYTE DEPLETERS |
GCN | 37075 |
HICL Sequence Number | 041378 |
HICL Sequence Number Description | FERRIC CITRATE |
Brand/Generic | Brand |
Proprietary Name | Auryxia |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | ferric citrate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, FILM COATED |
Route | ORAL |
Active Ingredient Strength | 210 |
Active Ingredient Units | mg/1 |
Substance Name | TETRAFERRIC TRICITRATE DECAHYDRATE |
Labeler Name | Akebia Therapeutics, Inc. |
Pharmaceutical Class | Iron [CS], Parenteral Iron Replacement [EPC], Phosphate Binder [EPC], Phosphate Chelating Activity [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA205874 |
Listing Certified Through | 2024-12-31 |
Package
NDC 59922-0631-01 (59922063101)
NDC Package Code | 59922-631-01 |
---|---|
Billing NDC | 59922063101 |
Package | 200 TABLET, FILM COATED in 1 BOTTLE (59922-631-01) |
Marketing Start Date | 2014-09-17 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 7.23105 |
Pricing Unit | EA |
Effective Date | 2024-02-01 |
NDC Description | AURYXIA 210 MG TABLET |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 2 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |